The pharmaceutical industry unfortunately is viewed negatively by the public. They believe that companies do little to ensure the safety of its medicines and that their main goal is to make profits at the expense of an unsuspecting public. Furthermore, people believe that drugs are really discovered in universities, research institutes or the NIH and that pharmaceutical companies simply license and manufacture new medicines. This is simply untrue. This talk will give concrete examples of the value that the pharmaceutical industry adds to the overall healthcare system. A robust pharmaceutical industry is crucial in coming up with new drugs to meet major medical needs in diseases such as Alzheimer’s, diabetes and heart disease.
The talk will feature:
Former Head Global R&D, Pfizer
John LaMattina was the Senior Vice President, Pfizer Inc. and President, Pfizer Global Research and Development. In this role, he oversaw the drug discovery and development efforts of more than 12,000 colleagues in the United States, Europe and Asia. LaMattina joined Pfizer as a medicinal chemist in 1997 and over the years, he held positions of increasing responsibility for Pfizer Central Research, including Vice President of U.S. Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998 and Senior Vice President of Worldwide Development in 1999.
During his tenure as Head of Global R&D, Pfizer produced new treatments for cancer, smoking cessation rheumatoid arthritis and AIDS. Dr. LaMattina is the author of numerous scientific publications, holds a number of U.S. patents and he is the author of “Drug Truths: Dispelling the Myths About Pharma R&D.” Dr. LaMattina has received a number of awards including the 1998 Boston College Alumni Award of Excellence in Science, an Honorary Doctor of Science degree from the University of New Hampshire in 2007, and the 2010 American Chemical Society Earle Barnes Award for Leadership in Chemical Research Management.
Dr. LaMattina is a Senior Partner at PureTech Ventures, he serves on the Board of Directors of Human Genome Sciences, the Board of Directors of Ligand Pharmaceuticals, and the Scientific Advisory Board of Trevena.
TIME: 10:30 a.m. - 11:45 a.m.
Space is limited. RSVP to Sharon Krueger at sharonkruegervirginia.edu or 434-243-1407.